Medicine News and Research

RSS

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Rush University College of Nursing professor receives Flame of Excellence Award from AACN

The American Association of Critical-Care Nurses will give the Flame of Excellence Award to Ruth Kleinpell at the 2010 National Teaching Institute & Critical Care Exposition, Washington, D.C., May 15-20.

21 May 2010

Researchers propose steps to enhance patient-physician communication to improve depression care

Because people with depression often do not recognize they have a problem or are unable to describe their distress, many do not seek treatment. About a quarter of those with major depression are undiagnosed, according to several studies, and fewer than half receive treatment.

21 May 2010

Living wills do not represent patients’ treatment preferences in end-of-life scenarios

Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.

21 May 2010

Group weight loss programs reduce risk for type 2 diabetes

The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

UF awarded $1.2M grant to support UF-HHMI Science for Life Program

Imagine a chemistry professor and a neuroscientist working together to test a new drug to fight Alzheimer's disease, or a biomedical engineer working with an orthopedic surgeon to help patients walk again.

21 May 2010

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Researchers at the Syracuse Veterans Affairs Medical Center in New York examined postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel and found that the postpolypectomy bleeding rate is significantly higher in patients undergoing polypectomy while taking clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs, but that the risk is small and the outcome is favorable.

21 May 2010

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

21 May 2010

Pressure treated playground structures are not harmful for children: Study

Pressure treated wooden playground structures do not live up to the bad reputation they have earned as being harmful to children, according to the findings of a new University of Alberta study.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

As US policymakers consider scaling back on its historic initiative to fight AIDS around the world and downsizing goals to combat tuberculosis, next-generation treatment and prevention strategies to significantly reduce the spread of HIV/AIDS and tuberculosis are now imminent. New science can dramatically change the trajectory of both deadly epidemics, according to a special new issue of the journal Clinical Infectious Diseases.

21 May 2010

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.

21 May 2010

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

The results of a major clinical study carried out at the Montreal Heart Institute by Dr. Jean-Claude Tardif are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Universit- de Montr-al.

21 May 2010

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.

21 May 2010

Hepatitis C affects so many people and yet not recognized as serious public health problem

May is Hepatitis Awareness Month, and you may find it surprising to learn an estimated 4 million Americans have been infected with Hepatitis C. This silent disease is three to five times more prevalent than HIV. Hepatitis C is the most common cause of liver transplants in the U.S.

21 May 2010

HemaCare announces commercial cell therapy collection agreement with Dendreon

HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Medicine News and Research

Blood biomarker underscores role of inflammation in vascular disease

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Rush University College of Nursing professor receives Flame of Excellence Award from AACN

Researchers propose steps to enhance patient-physician communication to improve depression care

Living wills do not represent patients’ treatment preferences in end-of-life scenarios

Group weight loss programs reduce risk for type 2 diabetes

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

UF awarded $1.2M grant to support UF-HHMI Science for Life Program

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

Pressure treated playground structures are not harmful for children: Study

Genentech to present new data for targeted cancer medicines at 46th ASCO

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

Hepatitis C affects so many people and yet not recognized as serious public health problem

HemaCare announces commercial cell therapy collection agreement with Dendreon

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Everything there is to know about biosimilars eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News